Pharvaris Supports HAE Community by Participating in Company-wide Activities Challenge for May 16th hae day :-)
May 16 2022 - 8:10AM
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing
novel, oral bradykinin-B2-receptor antagonists to treat and prevent
HAE attacks, building on its deep-seated roots in hereditary
angioedema (HAE), today announced company-wide support of today’s
Hereditary Angioedema International (HAEi) hae day :-) 2022, a
global awareness day for hereditary angioedema (HAE).
Pharvaris supported the HAE community by partaking in the hae
day :-) Activities Challenge for the 30 days leading up to hae day
:-). Pharvaris colleagues from across the globe participated in
both individual and team activities to promote overall wellbeing
and submitted more than 2,000,000 steps to help raise awareness of
HAE.
“hae day :-) and the Activities Challenge contribute to HAEi’s
objective to unify individuals across the globe raising awareness
of continuing medical need and innovative solutions to improve the
lives of people with HAE. Our participation in these initiatives
reflects our mission to improve outcomes for individuals living
with HAE,” said Berndt Modig, chief executive officer of Pharvaris.
“We are proud advocates of the HAE community and recognize the
opportunity we have to influence the lives of those affected by
HAE. At Pharvaris, we are focused on advancing our clinical
pipeline of oral bradykinin B2-receptor antagonists to bring novel
oral therapies to people living with HAE.”
About HAEHereditary angioedema is a rare and
potentially life-threatening genetic condition with symptoms that
include episodes of debilitating and often painful swelling in the
hands, feet, face (lips and tongue), gastrointestinal tract,
urogenital region, or airways. Attacks are unpredictable in
frequency, location, timing, and severity, with multiple types of
triggers. According to scientific publications, patients experience
a median of 14 attacks per year, and half of patients experience a
potentially life-threatening airway attack at least once in their
lifetime. Airway attacks are particularly dangerous and can lead to
asphyxiation. If left untreated, attacks can last multiple days and
are commonly painful, leading to multiple sick days and even
hospitalization. According to HAE International (HAEi), the global
umbrella organization for the world’s HAE patient groups, HAE
affects from 1:50,000 to 1:10,000 individuals globally, or at least
6,600 patients in the U.S. and at least 8,900 patients in the
EU.
About PharvarisPharvaris is a clinical-stage
company developing novel, oral bradykinin-B2-receptor antagonists
to treat and prevent HAE attacks, building on its deep-seated roots
in HAE. By directly targeting this clinically proven therapeutic
target with novel small molecules, the Pharvaris team aspires to
offer people with all sub-types of HAE more effective and
convenient alternatives to treat attacks, both on-demand and
prophylactically. The company brings together the best talent in
the industry with deep expertise in rare diseases and HAE. For more
information, visit https://pharvaris.com/.
Forward-Looking StatementsThis press release
contains certain forward-looking statements that involve
substantial risks and uncertainties. All statements contained in
this press release that do not relate to matters of historical fact
should be considered forward-looking statements, including, without
limitation, statements containing the words “believe,”
“anticipate,” “expect,” “estimate,” “may,” “could,” “should,”
“would,” “will,” “intend” and similar expressions. These
forward-looking statements are based on management’s current
expectations, are neither promises nor guarantees, and involve
known and unknown risks, uncertainties and other important factors
that may cause Pharvaris’ actual results, performance or
achievements to be materially different from its expectations
expressed or implied by the forward-looking statements. Such risks
include but are not limited to the following: the expected timing,
progress, or success of our clinical development programs,
especially for PHVS416 and PHVS719, which are in mid-stage clinical
trials; risks associated with the COVID-19 pandemic, which may
adversely impact our business, nonclinical studies, and clinical
trials; the timing of regulatory approvals; the value of our
ordinary shares; the timing, costs and other limitations involved
in obtaining regulatory approval for our product candidates PHVS416
and PHVS719, or any other product candidate that we may develop in
the future; our ability to establish commercial capabilities or
enter into agreements with third parties to market, sell, and
distribute our product candidates; our ability to compete in the
pharmaceutical industry and with competitive generic products; our
ability to market, commercialize and achieve market acceptance for
our product candidates; our ability to raise capital when needed
and on acceptable terms; regulatory developments in the United
States, the European Union and other jurisdictions; our ability to
protect our intellectual property and know-how and operate our
business without infringing the intellectual property rights or
regulatory exclusivity of others; our ability to manage negative
consequences from changes in applicable laws and regulations,
including tax laws; our ability to successfully remediate the
material weakness in our internal control over financial reporting
and to maintain an effective system of internal control over
financial reporting; changes in general market, political and
economic conditions, including as a result of the current conflict
between Russia and Ukraine; and the other factors described under
the headings “Cautionary Statement Regarding Forward-Looking
Statements” and “Item 3. Key Information—D. Risk Factors” in our
Annual Report on Form 20-F and other periodic filings with the
Securities and Exchange Commission.
These and other important factors could cause actual results to
differ materially from those indicated by the forward-looking
statements made in this press release. Any such forward-looking
statements represent management’s estimates as of the date of this
press release. New risks and uncertainties may emerge from time to
time, and it is not possible to predict all risks and
uncertainties. While Pharvaris may elect to update such
forward-looking statements at some point in the future, Pharvaris
disclaims any obligation to do so, even if subsequent events cause
its views to change. These forward-looking statements should not be
relied upon as representing Pharvaris’ views as of any date
subsequent to the date of this press release.
Contact:Maryann CiminoDirector of Corporate
Relationsmaryann.cimino@pharvaris.com +1-617-710-7305
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Apr 2023 to Apr 2024